Treatment-Related Cost for Advanced and Metastatic Pancreatic Cancer in JAPAN.
Author(s)
Kudo T1, Takumoto Y1, Ito C2, Akazawa M1
1Meiji Pharmaceutical University, Tokyo, Japan, 2The University of Tokyo, Tokyo, Japan
BACKGROUNDS and OBJECTIVES: In recent years, since many expensive anti-cancer drugs were introduced in the Japanese market, needs of their economic evaluations had been increased. Especially, for pancreatic cancer, treatment costs and adverse event(AE) related costs represent an important component because it is not a curable disease and information of burden of disease is limited. Also, a major treatment regimen, S-1 (tegafur, gimeracil and oteracil combination) is only used in Japan and Korea. We analyzed large-scale claim database to obtain treatment costs and AE-related costs for advanced and/or metastatic pancreatic cancer(AMPC). METHODS: We used health insurance claims data provided by the Medical Data Vision Co. Ltd. This database included 86,289 pancreas cancer patients diagnosed between April 2008 and December 2018. Patients were categorized and analyzed as followed by considering regimens recommended in Japan: initiated with gemcitabine (GEM), GEM+nab-paclitaxel, FOLFIRINOX, GEM+erlotinib, or S-1 after the first diagnosis of pancreatic cancer. Pancreatic cancer was defined by the ICD-10 code of C25. Patients with a record of surgery and/or radiation therapy were excluded. We analyzed costs of each treatment line, terminal care, and AE-related one, separately. RESULTS: We included 6,489 patients who diagnosed pancreatic cancer and received the first-line treatment without surgery and/or radiation therapy. The number of patients using GEM+nab-paclitaxel, FOLFIRINOX, and S-1 as the first-line treatment was 1942 (29.8%), 492 (7.6%), and 1491 (23.0%), respectively. The median duration of treatments and the median regimen costs per day were 101 days and 18,900 yen, 92 days and 18,000 yen, and 97 days and 4,850 yen, respectively. CONCLUSIONS: We can estimate treatment-related costs of AMPC from the large Japanese claim database. These data are useful to perform a cost-effectiveness analysis of pancreatic cancer regimens by reflecting patients in the Japanese clinical practice.
Code
PCN17